Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Prostate Cancer Prevention Endpoint May Have Been Key Problem As ODAC Votes Down BPH sNDAs

Dec 13 2010

• By Martin Berman-Gorvine

Related Content

Nothing Benign About It: BPH Drugs' Bids For Prostate Cancer Risk Reduction Voted Down By Advisory Committee

Dec 01 2010

Prostate Cancer Risk Reduction sNDAs Go Before ODAC, Pitting Statistical Versus Clinical Significance

Nov 29 2010

Tempers Flare At ODAC Meeting, And Pazdur Must Call "Order In The Court"

Dec 06 2010

"Risk Reduction" Indications Face A Higher Bar For Approval, May Require Specialized Prescribers

Dec 13 2010

Adult Vaccines Stand To Gain From Preventive Care Rule, Outreach Is Next

Jul 19 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window